Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Jefferam1on Apr 30, 2018 11:39am

256 Views

Post# 27958784

Antibe Facebook page response?

Does this response seem a litte odd on there Facebook page?
"All we tell you for now is that the Letter reflects the information we can share"

What info do they have that they can not yet share? Thoughts?

Anthony Laface Any news about Health Canada? That is where the real value for shareholders is ?

1

Manage

Like

Reply3d

Antibe Therapeutics Hi Anthony, Thanks for your message. We do not have news to announce about Health Canada. All we tell you for now is that the Letter reflects the information we can share. As soon as we have further news to report, we will release it appropriately. Thanks again for your interest!

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity